In this episode Mike Ward, Clarivate’s Head of Thought Leadership for Life sciences and healthcare, spoke to Johnny Ohlson, Founder of Touchlight, a company who has developed a novel synthetic DNA vector. In recent years, we've seen that by harnessing the power of DNA, it has been possible to achieve success in treating previously incurable hereditary diseases and even tackle major pandemics. However, whether the answer is cell or gene therapies or RNA vaccines, one thing they all have in common is that they require DNA in some form or another as the starting material. Through Touchlight, Johnny Ohlson and his talented team have built a business that can make DNA at unprecedented speed, scale and purity. Johnny, a serial entrepreneur not originally from a biopharma background, shares with us his story of breaking successfully into a complex industry. This podcast demonstrates that innovation at its heart is more about a combination of vision, relationships and talented people rather than prior experience.&nbsp;

Lighting the touch paper for next generation nucleic acid therapies 

In this episode of Conversations in Healthcare, Ergomed founder Dr. Miroslav Reljanović talks to Mike Ward about how the COVID-19 pandemic has nudged clinical trials towards greater efficiency and inclusivity – and what’s needed to make good on this promising trend.

Realizing the patient-friendly future of clinical trials

In this episode of Conversations in Healthcare, Mike Ward speaks with Dr. Grace Lomax, Clinical Director at Patient Connect, a part of Clarivate. Grace’s experience as a physician highlighted numerous unmet needs beyond just clinical issues – especially around healthcare literacy, education at the point of care, adherence and more. She discusses how Patient Connect uses technology and communication strategies to inform and support patients at the point of care, and shares examples of campaigns that improved outcomes in cancer, hypertension, rare disease and asthma.

How Patient Connect addresses unmet needs at the point of care

In this episode of Conversations in Healthcare, Matthew Arnold, Principal Analyst at Clarivate speaks with Dr. Kenton Johnston, Associate Professor of Health Management and Policy at Saint Louis University about disparities in the US health system. Matthew and Ken discuss both the historical context as well as the evolution of the system since the establishment of the Affordable Care Act, and how the entire spectrum of the healthcare system can work to address social determinants of health. Learn more in the full episode.

Social determinants: barriers to healthcare impacting racial and ethnic minorities

In this episode of Conversations in Healthcare, Mike Ward speaks with Naveed&nbsp;Saddiqi, Senior Partner at Novo Ventures, one of the largest venture capital groups in the life sciences sector. Naveed shares about the firm’s mandate to generate funds for the Novo Nordisk Foundation, how the pandemic impacted their investment strategy and what excites him most in the life sciences industry. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference&nbsp;(June 2021).&nbsp;

How Novo Ventures prioritized their investment strategy during the pandemic

In this episode of Conversations in Healthcare, Mike Ward speaks with&nbsp;Dr.&nbsp;Tim Guilliams, the co-founder and CEO of&nbsp;Healx.&nbsp;Healx&nbsp;is an artificial intelligence-powered technology company that's dedicated to helping rare disease patients access life improving treatments. Mike and Tim discuss the company’s innovative approach to drug discovery, choosing which rare diseases to target&nbsp;and how patients are shaping their priorities. Learn more in the full episode, which was recorded in collaboration with One Nucleus's ON Helix conference&nbsp;(June 2021).&nbsp;

How Healx uses AI to transform rare disease drug discovery 

In this episode of Conversations in Healthcare, Mike Ward&nbsp;speaks with Richard Erwin, general manager and managing director of Roche Products Limited (UK), which was recorded in collaboration with One Nucleus's ON Helix conference&nbsp;(June 2021). Richard shares how the pandemic has shifted Roche’s priorities&nbsp;and why the organization has heavily increased their investment in R&amp;D. Learn more in the full episode.&nbsp;

How the pandemic shifted Roche’s priorities and R&D investments 

In this episode of Conversations in Healthcare, Mike Ward&nbsp;speaks with Oriol Serra,&nbsp;former&nbsp;Head of Site Intelligence&nbsp;and&nbsp;Selection at Pfizer&nbsp;and&nbsp;Simon Andrews, Vice President&nbsp;of&nbsp;RWD&nbsp;Engagements&nbsp;and Innovations at Clarivate about optimizing&nbsp;patient-first&nbsp;clinical trial design&nbsp;and ensuring&nbsp;trial groups align to&nbsp;real-life populations and needs.&nbsp;&nbsp;&nbsp;The group discusses&nbsp;the ins and outs&nbsp;to bring&nbsp;clinical trial management in-house, how&nbsp;to&nbsp;modernize&nbsp;trial designs&nbsp;with emerging data and intelligence, overcoming key&nbsp;challenges and advice for other pharma and&nbsp;biotechs&nbsp;looking to go down this path. Learn more in the full episode.&nbsp;

Optimizing patient-first clinical trials with advanced site intelligence  

In this episode of Conversations in Healthcare, Mike Ward&nbsp;speaks with Carolyn Hynes, Director of Regulatory Intelligence at AstraZeneca,&nbsp;and Céline Rodier, Senior Health Policy Manager at Clarivate,&nbsp;about strategies and tools to gather and assess regulatory intelligence, as well as KPIs and approaches to demonstrating ROI within your organization. Get actionable takeaways in the full episode.&nbsp;&nbsp;

Showing the value of regulatory intelligence in pharma 

from Clarivate

Clarivate Conversations in Healthcare is a collection of candid interviews with key leaders and experts. Veteran industry journalist Mike Ward explores business challenges and opportunities the industry currently faces, including COVID-19, clinical innovation, deal making, emerging market dynamics, data and technology, new engagement models, patient centricity and much more.&nbsp;&nbsp;

Conversations in Healthcare

Follow